Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E27.11 EPS (ttm)3.23 Insider Own9.30% Shs Outstand2.28B Perf Week-2.27%
Market Cap215.71B Forward P/E14.17 EPS next Y6.18 Insider Trans0.05% Shs Float2.14B Perf Month2.18%
Income7.45B PEG3.94 EPS next Q1.37 Inst Own10.90% Short Float0.12% Perf Quarter4.75%
Sales49.93B P/S4.32 EPS this Y-43.60% Inst Trans-2.17% Short Ratio1.31 Perf Half Y-7.77%
Book/sh22.37 P/B3.91 EPS next Y10.50% ROA10.30% Target Price104.00 Perf Year-5.33%
Cash/sh2.02 P/C43.38 EPS next 5Y6.88% ROE23.10% 52W Range69.18 - 99.84 Perf YTD-7.52%
Dividend3.09 P/FCF36.44 EPS past 5Y-6.50% ROI8.60% 52W High-12.29% Beta0.53
Dividend %3.53% Quick Ratio0.50 Sales past 5Y-1.90% Gross Margin71.30% 52W Low26.58% ATR1.60
Employees109000 Current Ratio0.70 Sales Q/Q11.50% Oper. Margin19.20% RSI (14)50.78 Volatility1.46% 1.50%
OptionableYes Debt/Eq0.72 EPS Q/Q18.90% Profit Margin24.30% Rel Volume0.56 Prev Close87.85
ShortableYes LT Debt/Eq0.50 EarningsJul 21 BMO Payout53.50% Avg Volume1.96M Price87.57
Recom1.00 SMA20-0.10% SMA501.20% SMA200-0.86% Volume1,101,117 Change-0.32%
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Jul-04-20 04:07PM  
Jul-02-20 11:00AM  
08:53AM  
08:21AM  
06:04AM  
06:00AM  
Jul-01-20 10:40PM  
10:08PM  
06:35PM  
03:47PM  
10:42AM  
Jun-30-20 11:00AM  
Jun-29-20 04:34PM  
02:10PM  
02:06PM  
07:47AM  
Jun-28-20 11:36PM  
02:23PM  
Jun-26-20 07:32PM  
08:21AM  
07:34AM  
07:23AM  
Jun-25-20 11:30PM  
03:57PM  
03:49PM  
02:49PM  
01:31PM  
05:57AM  
Jun-22-20 02:51PM  
Jun-19-20 06:04PM  
04:32PM  
07:25AM  
Jun-18-20 05:53PM  
Jun-17-20 10:11AM  
09:56AM  
07:30AM  
04:06AM  
Jun-16-20 10:49AM  
09:00AM  
Jun-15-20 02:49PM  
Jun-12-20 10:16AM  
Jun-11-20 03:23PM  
11:37AM  
Jun-10-20 01:04PM  
12:58PM  
Jun-09-20 04:28PM  
10:31AM  
Jun-08-20 12:29PM  
10:59AM  
Jun-05-20 12:48PM  
10:21AM  
09:09AM  
07:34AM  
Jun-04-20 04:01PM  
11:12AM  
08:13AM  
Jun-03-20 06:24PM  
12:31PM  
07:39AM  
Jun-02-20 10:53AM  
Jun-01-20 10:05AM  
May-31-20 05:32PM  
May-28-20 02:26PM  
11:42AM  
10:26AM  
09:40AM  
May-27-20 07:25AM  
03:59AM  
May-22-20 07:46AM  
May-19-20 10:52AM  
10:13AM  
08:24AM  
May-18-20 12:22PM  
May-16-20 12:00AM  
May-15-20 02:59AM  
May-14-20 11:51AM  
02:43AM  
May-12-20 05:45PM  
May-08-20 11:04AM  
May-07-20 07:41AM  
May-05-20 03:26PM  
May-04-20 05:59PM  
03:50PM  
03:25PM  
08:55AM  
May-01-20 07:54AM  
Apr-30-20 12:52PM  
Apr-29-20 11:00AM  
10:05AM  
01:56AM  
01:48AM  
Apr-28-20 04:07PM  
02:10PM  
10:32AM  
08:51AM  
03:36AM  
01:24AM  
Apr-27-20 01:05PM  
10:43AM  
Apr-24-20 02:22PM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM